FDA imaging agent draft guidance expands allowable indications to four broad categories.
This article was originally published in The Gray Sheet
Executive Summary
FDA MEDICAL IMAGING DRUGS DRAFT GUIDELINE BROADENS INDICATIONS that can be claimed for imaging agents, incorporating suggestions made by the Council on Radionuclides and Radiopharmaceuticals in January. The four potential indications described in the draft guidance include structural localization; functional assessment or biochemical characterization; disease-specific indications; and management or decision-making indications. The Medical Imaging Drugs Advisory Committee met to discuss the draft on July 23, the third meeting of a series on developing the guidance document.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.